Back to Search
Start Over
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
- Source :
- Plesner, T, Dimopoulos, M A, Oriol, A, San-Miguel, J, Bahlis, N J, Rabin, N, Suzuki, K, Yoon, S S, Ben-Yehuda, D, Cook, G, Goldschmidt, H, Grosicki, S, Qin, X, Fastenau, J, Garvin, W, Carson, R, Renaud, T & Gries, K S 2021, ' Health-related quality of life in patients with relapsed or refractory multiple myeloma : treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial ', British Journal of Haematology, vol. 194, no. 1, pp. 132-139 . https://doi.org/10.1111/bjh.17435
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- In the phase 3 POLLUX trial, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival in patients with relapsed/refractory multiple myeloma (RRMM) compared with lenalidomide and dexamethasone (Rd) alone. Here, we present patient-reported outcomes (PROs) from POLLUX, assessed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaires. Changes from baseline are presented as least-squares mean changes with 95% confidence intervals (CIs) derived from a mixed-effects model. PRO assessment compliance rates were high and similar in both D-Rd and Rd groups through cycle 40 (week 156). In this on-treatment analysis, mean changes from baseline were significantly greater in EORTC QLQ-C30 global health status, physical functioning, and pain scores in the D-Rd group versus the Rd group at multiple time points; however, magnitude of changes was low, suggesting no meaningful impact on health-related quality of life (HRQoL). Subgroup results were similar to those in the overall population. In the POLLUX study, baseline HRQoL was maintained with prolonged D-Rd treatment. These findings complement the sustained and significant improvement in progression-free survival observed with D-Rd and supports its use in patients with RRMM. Clinical trial registration: NCT02076009.
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Population
Dexamethasone
03 medical and health sciences
0302 clinical medicine
Quality of life
Recurrence
relapsed/refractory multiple myeloma
Surveys and Questionnaires
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Patient Reported Outcome Measures
education
Lenalidomide
Aged
Pain Measurement
Salvage Therapy
education.field_of_study
business.industry
Antibodies, Monoclonal
Daratumumab
Cancer
Hematology
Middle Aged
daratumumab
medicine.disease
Progression-Free Survival
humanities
Confidence interval
health-related quality of life
Clinical trial
Treatment Outcome
patient-reported outcomes
030220 oncology & carcinogenesis
Quality of Life
Female
POLLUX
Multiple Myeloma
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 13652141 and 00071048
- Volume :
- 194
- Database :
- OpenAIRE
- Journal :
- British Journal of Haematology
- Accession number :
- edsair.doi.dedup.....aafc35b3c684119271589d6ef20af1d9